Clinical Trial Update: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC [Phase 2]

View source ↗

Summary

This report covers a Phase 2 clinical trial evaluating the efficacy and safety of combining sintilimab, anlotinib, and chemotherapy as neoadjuvant therapy in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED